Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3

被引:625
作者
Mäkinen, T
Jussila, L
Veikkola, T
Karpanen, T
Kettunen, MI
Pulkkanen, KJ
Kauppinen, R
Jackson, DG
Kubo, H
Nishikawa, SI
Ylä-Herttuala, S
Alitalo, K [1 ]
机构
[1] Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, Helsinki, Finland
[2] Univ Helsinki, Ludwig Inst Canc Res, Haartman Inst, Helsinki, Finland
[3] Univ Kuopio, AI Virtanen Inst, Dept Mol Med, Kuopio, Finland
[4] Univ Kuopio, Natl BioNMR Facil, Kuopio, Finland
[5] Kuopio Univ Hosp, Dept Oncol, SF-70210 Kuopio, Finland
[6] Univ Oxford, Mol Immunol Grp, Nuffield Dept Med, Oxford, England
[7] Kyoto Univ, Dept Mol Genet, Kyoto, Japan
关键词
D O I
10.1038/84651
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The lymphatic vasculature transports extravasated tissue fluid, macromolecules and cells back into the blood circulation. Recent reports have focused on the molecular mechanisms regulating the lymphatic vessels. Vascular endothelial growth factor (VEGF)-C and VEGF-D have been shown to stimulate lymphangiogenesis and their receptor, VEGFR-3, has been linked to human hereditary lymphedema. Here we show that a soluble form of VEGFR-3 is a potent inhibitor of VEGF-C/VEGF-D signaling, and when expressed in the skin of transgenic mice, it inhibits fetal lymphangiogenesis and induces a regression of already formed lymphatic vessels, though the blood vasculature remains normal. Transgenic mice develop a lymphedema-like phenotype characterized by swelling of feet, edema and dermal fibrosis. They survive the neonatal period in spite of a virtually complete lack of lymphatic Vessels in several tissues, and later show regeneration of the lymphatic vasculature, indicating that induction of lymphatic regeneration may also be possible in humans.
引用
收藏
页码:199 / 205
页数:7
相关论文
共 45 条
  • [1] Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3
    Achen, MG
    Roufail, S
    Domagala, T
    Catimel, B
    Nice, EC
    Geleick, DM
    Murphy, R
    Scott, AM
    Caesar, C
    Makinen, T
    Alitalo, K
    Stacker, SA
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 2000, 267 (09): : 2505 - 2515
  • [2] Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)
    Achen, MG
    Jeltsch, M
    Kukk, E
    Mäkinen, T
    Vitali, A
    Wilks, AF
    Alitalo, K
    Stacker, SA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (02) : 548 - 553
  • [3] SUPPRESSION OF RETINAL NEOVASCULARIZATION IN-VIVO BY INHIBITION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) USING SOLUBLE VEGF-RECEPTOR CHIMERIC PROTEINS
    AIELLO, LP
    PIERCE, EA
    FOLEY, ED
    TAKAGI, H
    CHEN, H
    RIDDLE, L
    FERRARA, N
    KING, GL
    SMITH, LEH
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (23) : 10457 - 10461
  • [4] LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan
    Banerji, S
    Ni, J
    Wang, SX
    Clasper, S
    Su, J
    Tammi, R
    Jones, M
    Jackson, DG
    [J]. JOURNAL OF CELL BIOLOGY, 1999, 144 (04) : 789 - 801
  • [5] Benjamin LE, 1998, DEVELOPMENT, V125, P1591
  • [6] BYRNE C, 1994, DEVELOPMENT, V120, P2369
  • [7] Vascular endothelial growth factor C induces angiogenesis in vivo
    Cao, YH
    Linden, P
    Farnebo, J
    Cao, RH
    Eriksson, A
    Kumar, V
    Qi, JH
    Claesson-Welsh, L
    Alitalo, K
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (24) : 14389 - 14394
  • [8] Mechanisms of angiogenesis and arteriogenesis
    Carmeliet, P
    [J]. NATURE MEDICINE, 2000, 6 (04) : 389 - 395
  • [9] Cardiovascular failure in mouse embryos deficient in VEGF receptor-3
    Dumont, DJ
    Jussila, L
    Taipale, J
    Lymboussaki, A
    Mustonen, T
    Pajusola, K
    Breitman, M
    Alitalo, K
    [J]. SCIENCE, 1998, 282 (5390) : 946 - 949
  • [10] Eriksson U, 1999, CURR TOP MICROBIOL, V237, P41